for a Brighter Tomorrow
JOIN MAILING LIST
PRESENTATION
PIPELINE
INVESTORS
ABOUT US
Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.
Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.
In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.
PRESS RELEASES
Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study
First and Largest of two concurrent Phase 3 trials on track [...]
Oramed Issues Letter to Shareholders with Updates on Oral Insulin and COVID-19 Vaccine
- Phase 3 Studies of Oral Insulin Underway and on Schedule [...]